X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The proceeds will also be used to fund company's clinical trials expanding N-803 (Anktiva), an interleukin-15 superagonist fusion protein, being developed for indications into multiple solid tumors, including BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oberland Capital
Deal Size: $320.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Details:
Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
The financing will fund company's ongoing business operations and pre-commercialization efforts as it continues to drive toward a potential regulatory approval of Anktiva (N-803), a novel IL-15 superagonist, plus BCG for BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nant Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 11, 2023
Details:
Anktiva™ (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex and has received breakthrough therapy and fast track designations from the U.S. FDA for BCG-unresponsive CIS non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
The vaccine, TUBERVAC-rBCG can be administered to children and adults both. Once DCGI approves Serum Institute's TB vaccine, the National Technical Advisory Group on Immunisation (NTAGI) will decide on its introduction.
Lead Product(s): BCG Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: TUBERVAC-rBCG
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Positive QUILT 3.032 trial for Anktiva (N-803) results in 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed complete response with duration of 26.6 months; cystectomy avoidance rate of 91% and 100% bladder cancer overall survival at 24 months.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
Data demonstrate for BCG-unresponsive bladder cancer patients who were treated with BCG plus N-803 (Anktiva) and the doubling of historic overall survival rates in patients with advanced pancreatic cancer who were treated with the Nant Cancer Vaccine.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Anktiva™ (N-803) is an IL-15RαFc Superagonist, a proprietary therapeutic cytokine designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
All data for QUILT-3.032, which is studying VesAnktiva plus BCG in subjects with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, have been locked and analyzed. The results continue to demonstrate a clinically meaningful benefit that is sustained.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: VesAnktiva
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
This agreement between BHARAT BIOTECH and BIOFABRI would guarantee the worldwide production and the supply of the future vaccine, MTBVAC in more than 70 countries with a high TB incidence, such as India, country with the highest TB burden in the world, with a 25% of all cases.
Lead Product(s): MTBVAC,BCG Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bharat Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 16, 2022
Details:
The combination of NantKwest’s Natural Killer (NK) cell platform and ImmunityBio’s immunotherapy fusion protein, immunomodulator, and adenovirus platforms have already resulted in complete responses in late stage, difficult to treat metastatic cancers.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: NantKwest
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 21, 2020
Details:
The UK study is part of an existing Australian-led trial, which launched in April and also has arms in the Netherlands, Spain and Brazil. The BCG vaccine is also being tested as a protection against COVID-19 in South Africa.
Lead Product(s): BCG Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2020
Details:
BCG-vaccinated participants had their first infection on average 16 weeks after vaccination, compared to 11 weeks for the placebo group. There was no difference in side effects.
Lead Product(s): BCG Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Vaccine
Partner/Sponsor/Collaborator: Hellenic Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
Tests to see if the century-old Bacille Calmette-Guerin (BCG) vaccine, widely used in Africa for tuberculosis, protects against the new coronavirus have also begun in the Netherlands and Australia.
Lead Product(s): BCG Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Details:
Researchers at Baylor College of Medicine in the US have started a clinical trial to assess tuberculosis vaccine, bacille Calmette-Guerin (BCG), for its activity against Covid-19.
Lead Product(s): BCG Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
The BRACE trial builds on previous studies which showed that BCG reduces the level of virus when people are infected with similar viruses to SARS-CoV-2.
Lead Product(s): BCG Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
